Iovance Biotherapeutics Inc
$ 6.21
43.09%
06 Aug - close price
- Market Cap 1,937,821,000 USD
- Current Price $ 6.21
- High / Low $ 6.39 / 5.63
- Stock P/E N/A
- Book Value 1.65
- EPS -0.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.48 %
- 52 Week High 6.39
- 52 Week Low 1.76
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Analyst Target Price
$8.22
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 |
| Reported EPS | -0.33 | -0.19 | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 |
| Estimated EPS | -0.17 | -0.1535 | -0.18 | -0.26 | -0.29 | -0.24 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.46 |
| Surprise | -0.16 | -0.0365 | 0 | 0.01 | -0.04 | -0.12 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | 0 |
| Surprise Percentage | -94.1176% | -23.7785% | 0% | 3.8462% | -13.7931% | -50% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2026-08-06 16:10:39
Iovance Biotherapeutics (NASDAQ: IOVA) reported stronger-than-expected Q2 2026 results, with adjusted loss per share narrower than anticipated and revenue exceeding forecasts, driven by robust sales of its cancer therapy Amtagvi. Shares jumped over 30% in premarket trading. The company also announced improved gross margins, a solid cash position, and plans to update its full-year guidance as demand for its products continues to grow.
2026-08-06 14:43:35
Iovance Biotherapeutics (IOVA) stock surged over 40% to a new 52-week high after reporting Q2 2026 earnings that significantly exceeded Wall Street expectations. The strong performance was attributed to its cancer therapy, Amtagvi. The company maintained its revenue outlook under review.
2026-08-06 13:43:35
Iovance Biotherapeutics (IOVA) stock reached a new 52-week high of $5.97, reflecting a 64.39% appreciation over the past year. The company, which specializes in cancer immunotherapies, currently trades at $6.21 with a market capitalization of $1.94 billion. This milestone follows better-than-expected Q2 2026 results, with revenue of $99.31 million and a narrower adjusted loss per share, driven by strong sales of its cancer therapy, Amtagvi.
2026-08-06 13:43:35
Iovance Biotherapeutics Inc. (IOVA) has granted inducement stock options for 139,930 shares to 17 new non-executive hires, signaling an aggressive post-Amtagvi expansion. These grants, with a $4.66 strike price and a three-year vesting period, suggest management's confidence in long-term growth following the FDA approval of its TIL cancer therapy. While the company faces high R&D costs and quarterly losses, it maintains a strong cash position, providing runway for commercialization efforts.
2026-08-06 13:43:35
Iovance Biotherapeutics (NASDAQ: IOVA) is experiencing a 31.57% stock increase driven by positive sentiment surrounding its Amtagvi trial progress and a new hiring wave. The company granted inducement stock options for 139,930 shares to 17 new non-executive hires, indicating a significant expansion post-FDA approval of its TIL therapy, Amtagvi. This move suggests management's confidence in future demand and commercial build-out, attracting traders despite the company's current losses as it transitions from development to commercialization.
2026-08-06 11:43:35
Iovance Biotherapeutics, Inc. (IOVA) announced strong Q2 revenue, reaching $99.3 million, significantly surpassing FactSet's estimated $87.8 million. This positive financial performance was released alongside other company updates, including recent regulatory approvals for its Amtagvi therapy in Australia and FDA clearance for a new clinical trial. The company specializes in developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients.
